Calliditas Therapeutics AB (publ) EBITDA 2011-2026 | CALT

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Calliditas Therapeutics AB (publ)

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-524 M	-377 M	-26.1 M	-133 M	-84.6 M	-56.4 M	-51.3 M	-	-	-	-

All numbers in SEK currency

Indicator range from annual reports

Maximum	Minimum	Average
-26.1 M	-524 M	-179 M

Quarterly EBITDA Calliditas Therapeutics AB (publ)

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-208 M	-	-	-159 M	-151 M	-	-	-66.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in SEK currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-66.6 M	-208 M	-146 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Drug manufacturers industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	-13.5 M	-	7.5 %	$ 6.35 M	USA
Aerie Pharmaceuticals AERI	-40 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	-19.8 M	-	10.11 %	$ 58.2 M	USA
Adamis Pharmaceuticals Corporation ADMP	-23.6 M	-	0.86 %	$ 117 M	USA
DURECT Corporation DRRX	-36.9 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	81.6 M	-	-39.89 %	$ 27.7 M	USA
Cronos Group CRON	-176 M	$ 2.64	-2.22 %	$ 1.36 B	Canada
Endo International plc ENDP	306 M	-	-	$ 28.9 M	Irlanda
Organogenesis Holdings ORGO	12.3 M	$ 2.42	1.26 %	$ 319 M	USA
Cumberland Pharmaceuticals CPIX	3.06 M	$ 4.18	-0.24 %	$ 58.8 M	USA
Catalent CTLT	-260 M	-	-	$ 11.5 B	USA
Alimera Sciences ALIM	6.82 M	-	-	$ 142 M	USA
Athenex ATNX	-65.5 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	-39.7 M	-	-	$ 2.06 B	France
Solid Biosciences SLDB	-178 M	$ 7.42	-1.07 %	$ 649 M	USA
Sonoma Pharmaceuticals SNOA	-3.57 M	$ 1.05	-5.41 %	$ 1.3 M	USA
Evoke Pharma EVOK	-7.43 M	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	-85.5 M	-	2.45 %	$ 38.1 M	Canada
Tilray TLRY	-1.37 B	$ 6.6	-4.28 %	$ 4.08 B	Canada
Jupiter Wellness JUPW	654 K	-	-	$ 33.6 M	USA
Bausch Health Companies BHC	2.23 B	$ 5.69	1.88 %	$ 2.08 B	Canada
Canopy Growth Corporation CGC	-95.6 M	$ 1.16	-3.33 %	$ 125 M	Canada
Veru VERU	-36.6 M	$ 2.33	-0.43 %	$ 314 M	USA
Harrow Health HROW	31.8 M	$ 40.28	-2.73 %	$ 1.48 B	USA
Viatris VTRS	3.51 B	$ 14.72	-0.64 %	$ 17.7 B	USA
Lannett Company LCI	-142 M	-	1.15 %	$ 7.11 M	USA
OrganiGram Holdings OGI	-91.8 M	$ 1.41	-2.15 %	$ 402 M	Canada
Evolus EOLS	-25.2 M	$ 5.24	0.38 %	$ 338 M	USA
Sundial Growers SNDL	-132 M	$ 1.5	-0.66 %	$ 3.37 M	Canada
Emergent BioSolutions EBS	-601 M	$ 8.15	1.49 %	$ 417 M	USA
Neoleukin Therapeutics NLTX	-100 M	-	-	$ 193 M	Canada
Pacira BioSciences PCRX	5.41 M	$ 25.4	-0.59 %	$ 1.17 B	USA
Radius Health RDUS	-53.2 M	-	-	$ 1.42 B	USA
ProPhase Labs PRPH	28.3 M	-	-	$ 5.07 M	USA
cbdMD YCBD	-2.86 M	$ 0.95	-2.09 %	$ 4.1 M	USA
Assertio Holdings ASRT	8.47 M	$ 18.05	0.03 %	$ 116 M	USA
PetIQ PETQ	81.6 M	-	1.64 %	$ 400 M	USA
Relmada Therapeutics RLMD	-59.1 M	$ 7.14	1.56 %	$ 282 M	USA
Recro Pharma REPH	4.65 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	-22.3 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	-16.1 M	$ 0.98	-2.4 %	$ 48.9 M	USA
PLx Pharma PLXP	-40.7 M	-	-27.8 %	$ 2.56 M	USA
Aurora Cannabis ACB	-283 M	$ 3.43	-2.42 %	$ 86.3 M	Canada
Zomedica Corp. ZOM	-82.3 M	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	-2.5 M	$ 0.87	2.85 %	$ 31.3 M	USA
Tricida TCDA	-153 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	-1.74 M	$ 0.56	-4.15 %	$ 2.4 M	China
TherapeuticsMD TXMD	-4.01 M	$ 2.12	2.17 %	$ 24.5 M	USA